Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 199

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Relevance of Half-Life in Drug Design: Miniperspective

Smith, Dennis A., Beaumont, Kevin, Maurer, Tristan S., Di, Li · 2018 · Journal of Medicinal Chemistry

Abstract

Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state. A half-life of 12-48 h is generally ideal for once daily dosing of oral drugs. If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concentrations. This may pose challenges to achieving optimal efficacy, safety, and patient compliance. If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged. This may pose problems with managing adverse effects and the design of efficient clinical trials. Half-life is a key parameter for optimization in research and development. Structural modification to affect clearance, and to a lesser extent volume of distribution, is the preferred means of modulating half-life. An effective approach to half-life optimization requires an understanding of the many pitfalls associated with its estimation and interpretation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.7b00969

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 31

  1. 10.1021/acs.jmedchem.5b00201 · doi:10.1021/acs.jmedchem.5b00201
  2. 10.1038/2071301a0 · DOI
  3. 10.1016/8756-3282(95)00445-9 · DOI · Paper page
  4. 10.1007/s40262-013-0071-8 · DOI
  5. 10.1124/dmd.115.067736 · DOI
  6. 10.1016/0002-8703(83)90006-6 · DOI · Paper page
  7. Plomp T. A., 1984, Arzneim. Forsch., 34, 513
  8. Anastasiou-Nana M., 1982, Int. J. Clin. Pharmacol. Ther. Toxicol., 20, 524
  9. 10.2165/00003088-198409020-00002 · DOI · Paper page
  10. Kannan R., 1985, Drug Metab. Dispos., 13, 646
  11. 10.1038/nrd3287 · DOI · Paper page
  12. 10.1021/jm5007935 · DOI
  13. Ding H., 2016, Applied Biopharmaceutics and Pharmacokinetics, 567
  14. Ummadi S., 2013, International Journal of Pharma Sciences, 3, 258
  15. 10.18433/J38W25 · DOI
  16. 10.5402/2012/528079 · DOI
  17. 10.1111/j.1365-2125.1986.tb02874.x · DOI · Paper page
  18. 10.2165/00003088-198815010-00001 · doi:10.2165/00003088-198815010-00001
  19. 10.1002/bdd.2510070102 · doi:10.1002/bdd.2510070102
  20. 10.1124/dmd.108.020479 · DOI · Paper page
  21. 10.2165/00003088-199630010-00003 · DOI
  22. 10.1002/jcph.734 · DOI
  23. 10.1002/cpt.576 · DOI
  24. 10.2174/1389200033489253 · DOI · Paper page
  25. 10.1111/j.1365-2125.1984.tb02362.x · DOI
  26. 10.1007/s11095-008-9787-9 · DOI · Paper page
  27. 10.1002/j.1552-4604.1995.tb04117.x · DOI · Paper page
  28. 10.1080/004982500406453 · doi:10.1080/004982500406453
  29. Nash J. F., 1980, J. Rheumatol., Suppl., 6, 12
  30. 10.1136/bmj.284.6326.1365 · doi:10.1136/bmj.284.6326.1365
  31. Hamdy R. C., 1982, Eur. J. Rheumatol. Inflammation, 5, 69

Cited by

See all 199

Metadata

Authors
Smith, D. A., Beaumont, K., Maurer, T. S., & Di, L.
Venue
Journal of Medicinal Chemistry
Published
2017-11-07
Volume
61
Issue
10
Pages
4273-4282
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2767714545
Cited by
199
References
1
FWCI
8.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relevance of Half-Life in Drug Design: Miniperspective. https://app.cochat.ai/papers/10.1021/acs.jmedchem.7b00969
The paper
Smith, D. A., Beaumont, K., Maurer, T. S., & Di, L. (2018). Relevance of Half-Life in Drug Design: Miniperspective. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.7b00969

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.